Generate Biomedicines, Inc. (GENB)
NASDAQ: GENB · Real-Time Price · USD
12.73
+0.21 (1.68%)
Oct 15, 2026, 12:10 PM EDT - Market open
Generate Biomedicines Revenue
Generate Biomedicines had revenue of $6.31M in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to $26.48M. In the year 2025, Generate Biomedicines had annual revenue of $31.89M with 55.89% growth. That makes Generate Biomedicines the 32,122nd largest company in the world by revenue and 4,245th in the United States.
Revenue (ttm)
$26.48M
Revenue Growth
+55.89%
P/S Ratio
61.75
Revenue / Employee
$84,881
Employees
312
Market Cap
1.63B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 31.89M | 11.43M | 55.89% |
| Dec 31, 2024 | 20.46M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
GENB News
- 1 day ago - Generate Biomedicines, Zealand Pharma enter protein therapeutics pact - TheFly
- 1 day ago - Generate Biomedicines and Zealand Pharma Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases - GlobeNewsWire
- 1 day ago - Zealand Pharma and Generate Biomedicines Enter Collaboration and License Agreement to Develop Protein Therapeutics Engineered with AI for Metabolic Diseases - GlobeNewsWire
- 14 days ago - Generate Biomedicines, Roswell Park dose first patient in GB-5267 trial - TheFly
- 14 days ago - Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored' CAR T Therapy for Ovarian Cancer - GlobeNewsWire
- 22 days ago - Generate Biomedicines Transcript: Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum - Transcripts
- 4 weeks ago - Generate Biomedicines Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 4 weeks ago - Generate Biomedicines Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts